RV568(窄谱p38 MAPK-α/γ抑制剂)抑制COPD炎症
研究评估RV568(p38 MAPK-α/γ及SRC家族激酶抑制剂)在COPD相关细胞与动物模型中的抗炎活性,并在COPD患者中开展14天试验。RV568在单核细胞和巨噬细胞中显示强效抗炎作用,与皮质类固醇联用提示协同。COPD患者吸入RV568(50 µg和100 µg)较安慰剂改善支扩前FEV1(分别69 mL和48 mL)并显著降低痰液丙二醛(p<0.05),痰细胞计数无变化,不良事件与安慰剂相似。
要点
- RV568在COPD相关细胞和动物模型中显示强效抗炎作用。
- COPD患者吸入RV568 50 µg和100 µg分别改善支扩前FEV1 69 mL和48 mL。
- RV568显著降低痰液丙二醛(p<0.05),痰细胞计数无变化。
核心结论
- RV568在COPD相关细胞和动物模型中显示强效抗炎作用,在14天COPD临床试验中耐受良好并显示适度临床获益。
研究设计与样本
- 在原代培养单核细胞、巨噬细胞和支气管上皮细胞及脂多糖和香烟烟雾暴露小鼠模型中测试RV568抗炎活性。
- 在COPD患者中开展14天试验评估RV568。
主要发现
- RV568在单核细胞和巨噬细胞中显示强效抗炎作用,常大于皮质类固醇或p38抑制剂Birb796。
- RV568与皮质类固醇联用在poly I:C刺激的BEAS-2B细胞和香烟烟雾模型中显示提示协同的抗炎作用。
- COPD患者吸入RV568(50 µg和100 µg)较安慰剂改善支扩前FEV1(分别69 mL和48 mL)。
- RV568显著降低痰液丙二醛(p<0.05),痰细胞计数无变化。
- RV568与安慰剂治疗期间不良事件相似。
临床怎么用
- RV568吸入50 µg或100 µg可能为COPD患者提供适度临床获益,但需进一步研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Novel anti-inflammatory approaches targeting chronically activated kinase pathways in chronic obstructive pulmonary disease (COPD) are needed. We evaluated RV568, a p38 mitogen-activated protein kinase-α and -γ and SRC family kinase inhibitor, in cellular and in vivo models relevant to COPD and examined its safety and efficacy in COPD patients.The anti-inflammatory activities of RV568 were tested in primary cultured monocytes, macrophages and bronchial epithelial cells and in vivo in lipopolysaccharide and cigarette smoke-exposed murine models. RV568 was evaluated in a 14-day trial in COPD patients.RV568 showed potent anti-inflammatory effects in monocytes and macrophages, which were often greater than those of corticosteroids or the p38 inhibitor Birb796. RV568 combined with corticosteroid had anti-inflammatory effects suggestive of a synergistic interaction in poly I:C-stimulated BEAS-2B cells and in the cigarette smoke model. In COPD patients, inhaled RV568 (50 µg and 100 µg) improved pre-bronchodilator forced expiratory volume in 1 s (69 mL and 48 mL respectively) and significantly reduced sputum malondialdehyde (p<0.05) compared to placebo, although there were no changes in sputum cell counts. Adverse events during RV568 and placebo treatment were similar.RV568 shows potent anti-inflammatory effects on cell and animal models relevant to COPD. RV568 was well-tolerated and demonstrated a modest clinical benefit in a 14-day COPD clinical trial.
引用
- Charron CE, Russell P, Ito K, et al. RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-α and -γ selectivity, suppresses COPD inflammation. Eur Respir J. 2017. PMID: 29074542. doi:10.1183/13993003.00188-2017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。